CN103141836A - Weight reducing capsule capable of enhancing immunity functions - Google Patents
Weight reducing capsule capable of enhancing immunity functions Download PDFInfo
- Publication number
- CN103141836A CN103141836A CN201310055848XA CN201310055848A CN103141836A CN 103141836 A CN103141836 A CN 103141836A CN 201310055848X A CN201310055848X A CN 201310055848XA CN 201310055848 A CN201310055848 A CN 201310055848A CN 103141836 A CN103141836 A CN 103141836A
- Authority
- CN
- China
- Prior art keywords
- weight reducing
- weight
- kgbw
- concurrently
- mouse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a weight reducing capsule capable of enhancing immunity functions. In the prior art, a safe and effective weight reducing health product has not been disclosed yet. To fill a gap in the prior art, the invention provides the weight reducing capsule capable of enhancing immunity functions. The capsule includes, by weight, 144 to 176 parts of konjak, 27 to 33 parts of propolis, 27 to 33 parts of pearl powder, 22.5 to 27.5 parts of a grape seed extract, 27 to 33 parts of American ginseng, 54 to 66 parts of a fleece-flower root, 36 to 44 parts of a lotus leaf and 22.5 to 27.5 parts of rhizoma alismatis. The weight reducing capsule provided by the invention has the advantages of improvement of immunity, reduction of weight and the like and is applicable to people with simple obesity.
Description
Technical field
The present invention relates to a kind of weight reducing capsule that strengthens immunity function that has concurrently.
Background technology
Society, obesity has become the able-bodied principal element of harm people, and prior art does not also have slimming health product safely and effectively.
Summary of the invention
The technical problem to be solved in the present invention is how to fill up the blank of prior art, and a kind of weight reducing capsule that strengthens immunity function that has concurrently is provided.
For solving the problems of the technologies described above, originally have the konjaku that the capsule 's content of the weight reducing capsule that strengthens immunity function comprises the 144-176 weight portion, the propolis of 27-33 weight portion, the pearl powder of 27-33 weight portion, the grape seed extract of 22.5-27.5 weight portion, the American Ginseng of 27-33 weight portion, the fleece-flower root of 54-66 weight portion, the lotus leaf of 36-44 weight portion, the rhizoma alismatis of 22.5-27.5 weight portion concurrently.
As optimization, every has the weight reducing capsule that strengthens immunity function concurrently and contains:
Chinese herbal medicine of the present invention is powdery.
The present invention has the weight reducing capsule that strengthens immunity function concurrently and has the advantages such as the immunity of enhancing, fat-reducing, and applicable Simple Obesity is taken.
The specific embodiment
Embodiment 1:
Said mixture is respectively charged in capsule, makes grain and have the weight reducing capsules A that strengthens immunity function, every 0.4g concurrently.
Embodiment 2:
Said mixture is respectively charged in capsule, makes and have the weight reducing capsule B that strengthens immunity function, every 0.4g concurrently.
Embodiment 3:
Said mixture is respectively charged in capsule, makes and have the weight reducing capsule C that strengthens immunity function, every 0.4g concurrently.
Strengthen the immunity function animal experiment
1 materials and methods
1.1 sample: by having the weight reducing capsules A that strengthens immunity function concurrently, content is filbert powdery, the 0.4g/ grain.The human body recommended amounts is everyone (adult) 3.6g every day, and sealing, shady and cool, dry place preserve, storage life 24 months, and in this sample, konjaku content is 40%, water-swellable can't gavage.The taro sample 1.44kg that unspells, the human body RD is everyone (adult) 2.16g every day, for experiment.
1.2 animal used as test: 192 of 18 ~ 22g Kunming kind (credit number: SCXK-(army) 2002-001) Healthy female mouse selecting Test Animal Centre, Academy of Military Medical Sciences, P.L.A breeding, be divided into and be four batches and tested, every batch is divided into 4 groups at random, 12 every group.A collection of internal organs/weight ratio pH-value determination pH, delayed allergy experiment, the HD50 value (HC of carrying out of immunity
50) mensuration and the mensuration of antibody-producting cell number; Two batches of immunity are talked and are cleaned up experiment; Three batches of immunity are carried out Turnover of Mouse Peritoneal Macrophages and are engulfed the chicken red blood cell experiment.Mouse lymphocyte transformation experiment and the NK cytoactive detection that ConA induces carried out in four batches of immunity.
1.3 dosage: everyone (by the 60kg batheroom scale) 2.16g every day of RD taro of unspelling has the weight reducing capsules A content (hereinafter to be referred as having the weight reducing capsules A that strengthens immunity function concurrently) that strengthens immunity function concurrently, is equivalent to 0.036g/ day/kg body weight.5 times, 10 times, 30 times of human body recommended amounts are established in experiment, and every day, 0.18g/kg BW, 0.36g/kg BW and 1.08g/kg BW were basic, normal, high dosage group.Tested material is prepared with distilled water, and per os gives the mouse tested material once a day, and gavage is surveyed every immune indexes after 32 days continuously.The mouse stomach volume is 0.2mL/10g BW.Establish a blank group (0g/kg BW) simultaneously, with distilled water, replace tested material, every day, the gavage volume was identical with the tested material group.
1.4 key instrument and reagent: animal balance, assay balance, clean bench, CO2gas incubator, centrifuge, 755 spectrophotometers, water bath with thermostatic control, ELIASA, microscope etc.
Aseptic operation apparatus, slide measure (precision 0.02mm), micro syringe (25 μ L), cell counter, the flat Tissue Culture Plate in 24 holes and 96 holes, the 96 U-shaped Tissue Culture Plates in hole, glass dish, gauze, test tube, slide frame, 200 eye mesh screens, timer, hemoglobin pipet, slide etc.
Sheep red blood cell (SRBC) (SRBC), physiological saline, Hank ' s liquid (pH7.2-7.4), the RPMI1640 nutrient solution, calf serum, mycillin, concanavalin A (ConA), 1% glacial acetic acid, the HCL solution of 1mol/L, acid isopropyl alcohol (the 96mL isopropyl alcohol adds the HCL solution 4mL of 1mol/L), MTT, PBS buffer solution (pH7.2-7.4), complement (GPS), the SA buffer solution, agarose, Dou Shi reagent (sodium acid carbonate 1.0g, high-potassium ferricyanide 0.2g, potassium cyanide 0.05g, adding distil water is to 1000mL), the YAC-1 cell, sodium lactate, the nitro tetrazolium chloride, PMS, oxidized coenzyme Ι, 0.2mol/L Tris-HCL buffer solution (pH8.2), 1%NP40, india ink, 0.1%Na
2cO
3, chicken red blood cell, methyl alcohol, Giemsa dye liquor etc.
1.5 experimental technique:
1.5.1 the mensuration of organ weight ratio value
Weigh rear dislocation of mouse is put to death, and gets spleen and thymus gland, removes most manadesma, with filter paper, blots the organ surface blood stains, weighs, and calculates spleen body weight ratio and thymus gland body weight ratio.
1.5.2 delayed allergy (DTH) experiment (the sufficient sole of the foot thickens method)
Get sheep blood, physiological saline washing 3 times, every mouse, through lumbar injection 2%(v/v, is prepared with physiological saline) hematocrit SRBC20 μ L, after injection, 24h measures left back sufficient sole of the foot section thickness, means the degree of DTH with the difference of sufficient sole of the foot thickness before and after attacking.
1.5.3ConA the mouse lymphocyte transformation experiment (mtt assay) of inducing
The aseptic spleen of getting, be placed in the little plate that fills appropriate aseptic Hank ' s liquid, with tweezers, gently spleen ground, and makes the individual cells suspension.Filter through 200 eye mesh screens, make cell suspension.Use Hank ' s liquid to wash 3 times, each centrifugal 10min (1000r/min).Then cell is suspended in the complete culture solution of 1mL, the microscopy counting, adjusting cell concentration is 3 * 10
6individual/mL.Again splenocyte suspension is divided two holes to add in 24 well culture plates, every hole 1mL, a hole adds 75 μ L ConA liquid (being equivalent to 7.5 μ g/mL) therein, and 5%CO in contrast, is put in another hole
2, 37 ℃ of CO
2cultivate 72h in incubator.Cultivate and finish front 4h, every hole sucks supernatant 0.7mL gently, adds 0.7mL containing the RPMI1640 nutrient solution of calf serum, adds MTT (5mg/mL) 50 μ L/ holes simultaneously, continues to cultivate 4h.After cultivating end, every hole adds 1mL acid isopropyl alcohol, and piping and druming mixes, and purple crystal is dissolved fully.Then this liquid is moved in cuvette to colorimetric estimation on 755 spectrophotometers, wavelength 570nm.Lymphocytic multiplication capacity deducts with the OD value that adds the ConA hole OD value that does not add the ConA hole and means.
1.5.4 the mensuration of antibody-producting cell number (Jerne improves slide method)
Get sheep blood, physiological saline washing 3 times, every mouse is through lumbar injection 2% (v/v prepares with physiological saline) hematocrit SRBC0.2mL.Mouse cervical vertebra dislocation by the SRBC immunity after 5 days is put to death, and takes out spleen, grinds gently spleen, makes cell suspension.Centrifugal (1000r/min) 10min, use Hank ' s liquid to wash 2 times, finally cell is suspended in 8mLHank ' s liquid.By after the agarose heating for dissolving, with the double Hank ' s of equivalent liquid, mix, the packing small test tube, every pipe 0.5mL, add 10% (v/v again in pipe, with the preparation of SA liquid) hematocrit SRBC50 μ L, splenocyte suspension 8 μ L, after mixing rapidly, be poured on the slide of brushing the agarose thin layer, do parallel plate, after agar solidifies, the slide level is buckled and is placed on horse, put into 37 ℃ of incubation 1h of CO2gas incubator, then join in slide frame groove with the complement (1: 8) of SA buffer solution dilution, after continuing incubation 1.5h, counting hemolysis plaque number.
1.5.5 the mensuration of HD50 value (HC50)
Get sheep blood, physiological saline washing 3 times, every mouse carries out immunity through lumbar injection 2% (v/v prepares with physiological saline) hematocrit SRBC0.2mL.After 5 days, extract eyeball and get blood in centrifuge tube, place about 1h, solidification blood and tube wall are peeled off, serum is fully separated out, the centrifugal 10min of 2000r/min, collect serum.Be 300 times with the SA buffer solution by the serum dilution, get 1mL and put in vitro, add successively 10% (v/v, with the preparation of SA buffer solution) hematocrit SRBC0.5mL, complement 1mL(presses dilution in 1: 8 with the SA buffer solution).Separately establish the not control tube of increase serum (replacing with the SA buffer solution).After putting in 37 ℃ of waters bath with thermostatic control insulation 15min, the ice bath cessation reaction.The centrifugal 10min of 2000r/min, get supernatant 1mL, adds Dou Shi reagent to 3mL.Simultaneously the get 10% hematocrit SRBC0.25mL of (v/v, with the preparation of SA buffer solution), add Dou Shi reagent to 4mL in another test tube, fully mix, after placing 10min, sentence control tube in 540nm and do blankly, measure and respectively manage OD value respectively.The amount of hemolysin means with HD50 value (HC50), is calculated as follows: OD value * extension rate during sample HD50 value=sample OD value/SRBC HD50
1.5.6 mouse carbon is cleaned up experiment
India ink (0.05mL/10g) by body weight from 4 times of mouse tail vein injection dilutions.Treat that prepared Chinese ink injects, timing immediately.Inject after prepared Chinese ink 2,10min, get blood 20 μ L from the angular vein clump respectively, and it be added to 2mL0.1%Na
2cO
3in solution.With 755 spectrophotometers at 600nm wavelength place's photometry density value (OD), with Na
2cO
3solution is made blank.Mouse is put to death, get liver and spleen is weighed.Be calculated as follows a:
K=(lgOD
1-lgOD
2)/(t
2-t
1) a=body weight ÷ (liver weight+spleen weight) * k
1/3
1.5.7 Turnover of Mouse Peritoneal Macrophages is engulfed chicken red blood cell experiment (half intracorporal method)
Mouse peritoneal injection 20% (v/v, with physiological saline, prepare) chicken red blood cell (2000r/min, 10min) suspension 1mL, interval 30min, the cervical vertebra dislocation is put to death, and through Intraperitoneal injection physiological saline 2mL., gets peritoneal macrophage washing lotion 1mL, drips respectively on 2 slides, put into the enamel box that is lined with wet gauze, 37 ℃ of incubator incubation 30min of dislocation.Incubate completely, rinsing in physiological saline, to remove not paster cell.Dry, fix with 1: 1 acetone methanol solution, the dyeing of 4% (v/v) Giemsa-phosphate buffer, then dry with the distilled water rinsing.Under the oil mirror, count, 100 macrophages of every counting are calculated as follows phagocytic rate and phagocytic index:
The macrophage number of the macrophage number of phagocytic percentage (%)=engulf chicken red blood cell/counting * 100
The macrophage number of the chicken red blood cell sum/counting of phagocytic index=engulfed
1.5.8NK the mensuration of cytoactive (lactate dehydrogenase L DH determination method)
Before experiment, 24h, by target cell YAC-1 cultivations of being gone down to posterity, washes 3 times with Hank ' s liquid before application, with the RPMI1640 complete culture solution adjustment cell concentration that contains 10% calf serum, is 4 * 10
5individual/mL.Tested mouse draws neck to put to death, and the aseptic spleen of getting, make splenocyte suspension, uses Hank ' s liquid to wash 2 times, each centrifugal 10min(1000r/min).Abandoning supernatant upsprings cytoplasm, add the 0.5mL aqua sterilisa 20 seconds, add again 0.5mL2 times of Hank ' s liquid and 8mLHank ' s liquid after splitting erythrocyte, 1000r/min, 10min is centrifugal, resuspended containing the RPMI1640 complete culture solution of 10% calf serum with 1mL, the microscopy counting, adjusting cell concentration with the RPMI1640 complete culture solution is 2 * 10
7individual/mL.Making to imitate the target ratio is 50: 1.Get each 100 μ L of target cell and effector cell, add in U-shaped 96 well culture plates; Target cell Spontaneous release hole adds target cell and each 100 μ L of nutrient solution, and the maximum release aperture of target cell adds target cell and each 100 μ L of 1%NP40; Above-mentioned every three parallel holes of all establishing, 37 ℃, 5%CO
2cultivate 4h in incubator, by 96 orifice plates with the centrifugal 5min of 1500r/min, draw at the bottom of supernatant 100 μ L horizontalizations in 96 well culture plates in every hole, add LDH matrix liquid 100 μ L, reaction 3-10min, then every hole adds the HCl solution 30 μ L cessation reactions of 1mol/L, and at ELIASA 490nm place's photometry density value (OD), the NK cytoactive is calculated as follows: NK cytoactive (%)=(reacting hole OD-Spontaneous release hole OD)/(maximum release aperture OD-Spontaneous release hole OD) * 100
The preparation of LDH matrix liquid: sodium lactate 5 * 10
-2mol/L
Nitro tetrazolium chloride 6.6 * 10
-4mol/L
PMS 2.8 * 10
-4mol/L
Oxidized coenzyme Ι 1.3 * 10
-3mol/L
Mentioned reagent is dissolved in the Tris-HCl buffer solution of 0.2mol/L (pH8.2)
1.6 experimental data is carried out homogeneity test of variance with SPSS software to each experiment initial data, meets data information that " variance is neat " require and carries out statistical disposition with the comparative approach in twos of mean between one-way analysis of variance method and a plurality of experimental group and control group; Data information to abnormal or heterogeneity of variance carries out suitable variable conversion, after meeting " the normal state variance is neat " requirement, by the data of conversion gained, carries out statistical disposition.
2 results
2.1 have the impact of the weight reducing capsules A of enhancing immunity function on Mouse Weight concurrently
Table 1 is respectively organized the initial body weight of mouse
From table 1, between 0.18g/kgBW group, 0.36g/kgBW group, 1.08g/kgBW group and 0g/kgBW group relatively, there are no significant for difference (P>0.05) for the initial body weight of mouse, and the initial body weight of mouse is comparatively balanced between each group.
Table 2 has the impact of the weight reducing capsules A of enhancing immunity function on Mouse Weight concurrently
From table 2, per os gives the weight reducing capsules A 32 days that having concurrently of mouse various dose strengthen immunity function, the body weight of mouse is a collection of in immunity, comparison between two batches of immunity, three batches of immunity, four batches of each dosage groups of immunity and control group (0g/kgBW), there are no significant for difference (P>0.05), has the weight reducing capsules A that strengthens immunity function concurrently Mouse Weight is had no adverse effects.
2.2 have the impact of the weight reducing capsules A of enhancing immunity function on mice organs/body weight ratio concurrently
Table 3 has the impact of the weight reducing capsules A of enhancing immunity function on mouse spleen/body weight ratio concurrently
| Dosage | Number of animals (only) | Spleen/body weight ratio (mg/g) | The P value |
| 0g/kgBW | 12 | 5.20±0.71 | —— |
| 0.18g/kgBW | 12 | 4.98±0.80 | 0.754 |
| 0.36g/kgBW | 12 | 4.94±0.57 | 0.651 |
| 1.08g/kgBW | 12 | 5.23±0.42 | 0.999 |
From table 3, per os gives the weight reducing capsules A 32 days that having concurrently of mouse various dose strengthen immunity function, each experimental group spleen/body weight ratio and 0g/kgBW group are relatively, there are no significant for difference (P>0.05), have concurrently the weight reducing capsules A that strengthens immunity function on the spleen of mouse/body weight ratio without impact.
Table 4 has the impact of the weight reducing capsules A of enhancing immunity function on mouse thymus/body weight ratio concurrently
| Dosage | Number of animals (only) | Thymus gland/body weight ratio (mg/g) | The P value |
| 0g/kgBW | 12 | 2.92±0.50 | —— |
| 0.18g/kgBW | 12 | 3.20±0.51 | 0.429 |
| 0.36g/kgBW | 12 | 3.14±0.62 | 0.625 |
| 1.08g/kgBW | 12 | 3.15±0.47 | 0.590 |
From table 4, per os gives the weight reducing capsules A 32 days that having concurrently of mouse various dose strengthen immunity function, each experimental group thymus gland/body weight ratio and 0g/kgBW group are relatively, there are no significant for difference (P>0.05), have concurrently the weight reducing capsules A that strengthens immunity function on the thymus gland of mouse/body weight ratio without impact.
2.3 have the impact of the weight reducing capsules A of enhancing immunity function on the mouse cell immunologic function concurrently
Table 5 has the impact of the weight reducing capsules A of enhancing immunity function on mouse delayed allergy (DTH) concurrently
| Dosage | Number of animals (only) | Swelling degree of the paw (mn) | The P value |
| 0g/kgBW | 12 | 0.51±0.14 | —— |
| 0.18g/kgBW | 12 | 0.55±0.17 | 0.918 |
| 0.36g/kgBW | 12 | 0.71±0.18 | 0.017* |
| 1.08g/kgBW | 12 | 0.69±0.17 | 0.035* |
*P﹤0.05
From table 5, per os gives the weight reducing capsules A 32 days that having concurrently of mouse various dose strengthen immunity function, its swelling degree of the paw compares between 0.36g/kgBW and 1.08g/kgBW group and 0g/kgBW group, difference has conspicuousness (P ﹤ 0.05), has the weight reducing capsules A that strengthens immunity function concurrently and can improve the delayed allergy ability of mouse in 0.36g/kgBW and 1.08g/kgBW group.
Table 6 has the impact of the mouse lymphocyte transformation experiment that the weight reducing capsules A that strengthens immunity function induces ConA concurrently
| Dosage | Number of animals (only) | Lymphopoiesis ability (OD difference) | The P value |
| 0g/kgBW | 12 | 0.201±0.086 | —— |
| 0.18g/kgBW | 12 | 0.260±0.128 | 0.377 |
| 0.36g/kgBW | 12 | 0.287±0.113 | 0.124 |
| 1.08g/kgBW | 12 | 0.323±0.084 | 0.017* |
*P﹤0.05
From table 6, per os gave the weight reducing capsules A that has the enhancing immunity function concurrently of mouse various dose after 32 days, its lymphocytic multiplication capacity compares between 1.08g/kgBW group and 0g/kgBW group, difference has conspicuousness (P ﹤ 0.05), has the weight reducing capsules A that strengthens immunity function concurrently and can improve in the 1.08g/kgBW group mouse lymphocyte conversion capability that ConA induces.
2.4 have the impact of the weight reducing capsules A of enhancing immunity function on humoral immunity concurrently
Table 7 has the impact of the weight reducing capsules A of enhancing immunity function on mouse antibodies cellulation number concurrently
| Dosage | Number of animals (only) | Hemolysis plaque number (* 10 3/ full spleen) | The P value |
| 0g/kgBW | 12 | 130±51 | —— |
| 0.18g/kgBW | 12 | 124±53 | 0.990 |
| 0.36g/kgBW | 12 | 186±74 | 0.104 |
| 1.08g/kgBW | 12 | 174±80 | 0.250 |
From table 7, per os gives the weight reducing capsules A 32 days that having concurrently of mouse various dose strengthen immunity function, each experimental group antibody-producting cell number and 0g/kgBW group are relatively, there are no significant for difference (P>0.05), have concurrently strengthen immunity function the weight reducing capsules A on mouse antibodies cellulation number without impact.
Table 8 has the weight reducing capsules A of enhancing immunity function concurrently to mouse HD50 value (HC
50) impact
| Dosage | Number of animals (only) | Sample HD50 value | The P value |
| 0g/kgBW | 12 | 87±42 | —— |
| 0.18g/kgBW | 12 | 106±59 | 0.663 |
| 0.36g/kgBW | 12 | 101±53 | 0.826 |
| 1.08g/kgBW | 12 | 93±48 | 0.981 |
From table 8, per os gives the weight reducing capsules A 32 days that having concurrently of mouse various dose strengthen immunity function, each experimental group HD50 value and 0g/kgBW group are relatively, there are no significant for difference (P>0.05), have concurrently strengthen immunity function the weight reducing capsules A on mouse HD50 value without impact.
2.5 have the impact of the weight reducing capsules A of enhancing immunity function on mouse monokaryon-macrophage phagocytic function concurrently
Table 9 has the weight reducing capsules A that strengthens immunity function concurrently and carbon is cleaned up to the impact of ability
| Dosage | Number of animals (only) | Phagocytic index (a) | The P value |
| 0g/kgBW | 12 | 6.41±0.63 | —— |
| 0.18g/kgBW | 12 | 6.38±0.68 | 0.998 |
| 0.36g/kgBW | 12 | 6.68±0.60 | 0.571 |
| 1.08g/kgBW | 12 | 7.04±0.47 | 0.037* |
*P﹤0.05
From table 9, per os gives the weight reducing capsules A 32 days that having concurrently of mouse various dose strengthen immunity function, its carbon is cleaned up ability and is compared between 1.08g/kgBW group and 0g/kgBW group, difference has conspicuousness (P ﹤ 0.05), has the carbon that the weight reducing capsules A that strengthens immunity function can improve mouse in the 1.08g/kgBW group concurrently and cleans up ability.
Table 10 has the weight reducing capsules A that strengthens immunity function concurrently and mouse macrophage is engulfed to the impact of chicken red blood cell phagocytic rate
| Dosage | Number of animals (only) | Phagocytic rate (%) | The P value |
| 0g/kgBW | 12 | 22±6 | —— |
| 0.18g/kgBW | 12 | 26±7 | 0.549 |
| 0.36g/kgBW | 12 | 27±8 | 0.270 |
| 1.08g/kgBW | 12 | 31±10 | 0.028* |
*P﹤0.05
From table 10, per os gives the weight reducing capsules A 32 days that having concurrently of mouse various dose strengthen immunity function, its phagocytic rate compares between 1.08g/kgBW group and 0g/kgBW group, difference has conspicuousness (P ﹤ 0.05), and the weight reducing capsules A that has the enhancing immunity function concurrently can improve mouse macrophage in the 1.08g/kgBW group and engulf the chicken red blood cell phagocytic rate.
Table 11 weight reducing capsules A is engulfed the impact of chicken red blood cell phagocytic index on mouse macrophage
| Dosage | Number of animals (only) | Phagocytic index | The P value |
| 0g/kgBW | 12 | 0.33±0.10 | —— |
| 0.18g/kgBW | 12 | 0.37±0.14 | 0.840 |
| 0.36g/kgBW | 12 | 0.47±0.15 | 0.053 |
| 1.08g/kgBW | 12 | 0.48±0.17 | 0.034* |
*P﹤0.05
From table 11, per os gives the weight reducing capsules A 32 days that having concurrently of mouse various dose strengthen immunity function, its phagocytic index compares between 1.08g/kgBW group and 0g/kgBW group, difference has conspicuousness (P ﹤ 0.05), and the weight reducing capsules A that has the enhancing immunity function concurrently can improve mouse macrophage and engulf the chicken red blood cell phagocytic index.
2.6 have the impact of the weight reducing capsules A of enhancing immunity function on the NK cells in mice activity concurrently
Table 12 has the impact of the weight reducing capsules A of enhancing immunity function on the NK cells in mice activity concurrently
| Dosage | Number of animals (only) | NK cytoactive (%) | The P value |
| 0g/kgBW | 12 | 38.7±3.2 | —— |
| 0.18g/kgBW | 12 | 36.8±5.2 | 0.699 |
| 0.36g/kgBW | 12 | 42.5±5.4 | 0.193 |
| 1.08g/kgBW | 12 | 43.6±6.4 | 0.063 |
From table 12, per os gives the weight reducing capsules A 32 days that having concurrently of mouse various dose strengthen immunity function, each experimental group NK cytoactive and 0g/kgBW group are relatively, there are no significant for difference (P>0.05), has the weight reducing capsules A that strengthens immunity function concurrently active in impact on NK cells in mice.
3 brief summaries
Per os gives the weight reducing capsules A 32 days that having concurrently of mouse various dose strengthen immunity function, with the 0g/kgBW group relatively, the 0.36g/kgBW group can improve the delayed allergy ability (P ﹤ 0.05) of mouse; 1.08g/kgBW group can improve mouse delayed allergy ability (P ﹤ 0.05), improve mouse lymphocyte conversion capability (P ﹤ 0.05) that ConA induces, the carbon that improves mouse is cleaned up ability (P ﹤ 0.05), improve mouse macrophage engulfs chicken red blood cell phagocytic rate (P ﹤ 0.05), improves mouse macrophage and engulf chicken red blood cell phagocytic index (P ﹤ 0.05).Each dosage group has no adverse effects to weight of mice.Known to the criterion that strengthens the immunity health food according to " health food check and assessment technique standard " (2003 editions), have the weight reducing capsules A that strengthens immunity function concurrently and there is the effect that strengthens immunity function.
Replace having the weight reducing capsules A that strengthens immunity function concurrently with having the weight reducing capsule B that strengthens immunity function, the weight reducing capsule C that has the enhancing immunity function concurrently concurrently, repeat above-mentioned animal examination experiment, result is without significant change.
Above-mentioned experiment demonstration, the present invention has the weight reducing capsule that strengthens immunity function concurrently and has obvious enhancing immunity function, and long-term taking, without digestive discomfort.
The weight losing function human feeding trial
1.2. tested crowd: Simple Obesity, through health check-up, without dysfunctions such as the obvious heart, liver, courage, kidneys.
1.2.1. experimenter's choice criteria: more than 18 years old, below 65 years old, 20% of the body weight that is above standard.
1.2.2. SBW: adult's SBW (looking forward or upwards)=[height (cm) – 100] * 0.9
1.2.3, overweight degree %=(body weight Kg-SBW Kg) and xloo%/SBW
1.3. experimenter's exclusion standard:
1.3.1. merge intentionally, the serious primary diseases such as liver, kidney and hemopoietic system the mental patient.
1.3.2. edible tested material in accordance with regulations, can't decision-making function or data is not congruent affects function or security judgement person.
1.4. test-meal method: take every day and have the weight reducing capsules A 3 times that strengthens immunity function, each 3, continuous 35 days concurrently.
1.5. instrument and reagent: RG2-120 type scale, Wuxi City weighing apparatus factory produces.Sebum thickness measurer is Scientific Inst., State Physical Culture and Sports Commission's development.The bioelectrical impedance analysis instrument, U.S. biodynamics company produces.F-820 type blood counting instrument, urinate ten analyzers (German Bao Ling Man produce), RA100 automatic clinical chemistry analyzer (U.S.'s product), the biochemical reagents box all by living company provide.Treadmill power meter HELLIGE kinematic system Mc ditronic40-3 Germany He Lige company produces.
2。Observation index:
Observe 5 weeks, indices respectively tests one once when the test-meal experiment starts and finishes.
2.1. Symptom Observation:
Adopt integration method, the subjective symptoms such as diet, sleep, stool and urine, tired, weak, irritated, hidrosis of take are index, with the questionnaire form, by each symptom weight (severe 3 minutes, moderate 2 minutes, light disease 1 minute) statistics integrated value before and after test-meal, and improve (each doing well,improving 2 is divided into produce effects, improves 1 and is divided into effectively) calculating improvement rate with regard to its cardinal symptom.
2.2. body weight and height: emptying stool and urine before measuring, to take off one's shoes, the treatment forebody-afterbody is resurveyed and is regularly all worn same clothes and measure in same scale.
2.3. bioelectrical impedance analysis: measure the human body body fat rate, body fat weight
2.4. measurements of the chest, waist and hips are measured:
2.4.1. chest measurement: with the chest girth of two breast root levels.
2.4.2. waistline: the abdomen girth of flat navel.
2.4.3. hip circumference: with the girth of both sides greater trochanter of femur level.
2.5. sebum thickness measurement: measure position:
2.5.1. right triceps muscle of arm belly of muscle mid point.
2.5.2. right angulus inferior scapulae.
2.5.3. the other 2cm of right navel.
2.5.4. right anterior superior spine.
2.6. security is observed:
2.6.1. Blood routine examination
Red blood cell count(RBC), hemoglobin, white blood cell count(WBC).
2.6.2. Biochemical Indexes:
Seralbumin ALB, total protein TP, darling renal function (glutamic-oxalacetic transaminease AST, glutamic-pyruvic transaminase ALT, urea UREA, creatinine CRE), uric acid (UA), blood fat (total courage all pure TC, triglyceride TG).
2.6.3. Abdominal B type ultrasonography, electrocardiogram, x-ray fluoroscopy of chest.
2.7. maximal oxygen uptake test: the experimenter, before and after fat-reducing, uses cycle ergometer to measure exercise tolerance (50 watts of power, 5 minutes time).Application Telemetric Heart recorder, though record the large oxygen demand that exercise heart rate is inferred the experimenter.
3. result:
3.1. physical data:
Observe altogether experimenter's 30 examples, the male sex's 5 examples, women's 25 examples, minimum 22 years old of age, the oldest 63 years old, average 45.23 scholar 10.01 years old.The fat course of disease is the longest 24 years, the shortest 1 year, average 8.47 soil 6.80 years.
3.2. result statistics:
3.2.1. body weight and body fat decline situation before test-meal:
Body weight and body fat statistics before and after table 1. test-meal
| Project | Before test-meal | After test-meal | Difference |
| Body weight | 77.70±16.31 | 76.37±16.27 | -1.33±1.16** |
| Body fat (%) | 39.37±6.08 | 38.18±6.10 | -1.19±2.10** |
| Body fat weight (Kg) | 31.20±11.72 | 30.08 soil 11.70 | -1.12±0.98** |
**P<0.01
3.2.2. before and after test-meal, measurements of the chest, waist and hips and sebum change:
Measurements of the chest, waist and hips and sebum varied in thickness statistics (n=30) (X ± SD) before and after table 2. test-meal
| Project | Before test-meal | After test-meal | Difference |
| Chest measurement (cm) | 101.52±8.35 | 101.15±8.54 | 0.37±0.90* |
| Waistline (cm) | 91.93±12.87 | 90.32±12.55 | 1.62±1.67** |
| Hip circumference (cm) | 106.72±10.18 | 105.20 soil 9.83 | 1.52±2.13** |
| Triceps muscle of arm sebum (mm) | 51.28±14.78 | 50.00±14.18 | 1.28±2.12** |
| Angulus inferior scapulae sebum (mm) | 45.00±12.57 | 43.90±11.79 | 1.10±2.78* |
| Abdomen arm sebum (mm) | 53.97±12.57 | 52.03 soil 12.06 | 1.93±2.08** |
| Ilium sour jujube sebum (mm) | 42.13±7.55 | 40.77 soil 7.22 | 1.37±1.79** |
**P<0.01
3.2.3 cardinal symptom is improved situation
Table 3. cardinal symptom is improved situation
| Cardinal symptom | Number of cases | Produce effects | Effectively | Invalid | Efficient (%) |
| Lassitude and weak | 16 | 0 | 10 | 6 | 62.50 |
| Constipation | 12 | 1 | 6 | 5 | 58.33 |
| Irritated | 20 | 0 | 10 | 10 | 50.00 |
3.2.4 clinical symptoms integration statistics:
Table 4. clinical symptoms integration statistics: (X ± SD)
| Number of cases | Before test-meal | After test-meal |
| 30 | 9.03 soil 6.29 | 6.83±5.26*** |
***P<0.001
3.2.5. the security indices detects:
Table 5. security indices detects
| Project | Number of cases | Before test-meal | After test-meal |
| TP（g/L） | 30 | 77.64 soil 5.26 | 77.56 soil 4.56 |
| ALB（g/L） | 30 | 43.53 soil 3.77 | 44.30 soil 4.23 |
| ALT（u/L） | 30 | 22.97 soil 10.20 | 21.73 soil 10.25 |
| AST（u/L） | 30 | 18.20 soil 8.25 | 17.13 soil 7.13 |
| GLU（mmol/L） | 30 | 5.04 soil 0.68 | 5.09 soil 0.89 |
| UREA（mmol/L） | 30 | 4.48 soil 1.00 | 4.27 soil 1.40 |
| CRE（umol/L） | 30 | 95.37 soil 14.13 | 96.27 soil 12.05 |
| UA（umol/L） | 30 | 325.47 soil 76.61 | 338.33 soil 79.30 |
| TC（umol/L） | 30 | 5.62 soil 76.61 | 5.67 soil 1.15 |
| TG（umol/L） | 30 | 1.60 soil 0.81 | 1.63 soil 0.76 |
| HGB（g/L） | 30 | 138.83 soil 13.51 | 141.63 soil 11.69 |
| RBC（×10 12/L） | 30 | 4.60 soil 0.40 | 4.69 soil 0.40 |
| WBC（×10 9/L） | 30 | 6.42 soil 1.42 | 6.81 soil 1.33 |
Indices before and after the test-meal all in normal range (NR).
3.2.6 the variation of maximal oxygen uptake
The variation of maximal oxygen uptake before and after table 6. test-meal: (L/min, X ± SD)
| Number of cases | Before test-meal | After test-meal |
| 30 | 2.72 soil 0.29 | 2.69 soil 0.31 |
P<0.05
3.2.7. Abdominal B type ultrasonography, electrocardiogram, the x-ray fluoroscopy of chest detects, and all belongs to normal range (NR).
Result and judgement:
30 routine Simple Obesities are taken on request and are had the weight reducing capsules A that strengthens immunity function concurrently, weight average decline 1.33+1.16Kg after 5 weeks, body fat weight decline 1.12+0.98Kg, body fat decline 1.19+2.10. waist, hip circumference and the triceps muscle of arm, angulus inferior scapulae, stomach wall, ilium sour jujube sebum reduce, pairing T check P before and after test<O.01, there is significance,statistical.This product is to lassitude and weak, and the symptoms such as agitation, constipation are improved.Before and after test-meal, the clinical health check-up indexs such as hemoglobin, red blood cell, leucocyte, total serum protein, albumin, glutamic-oxalacetic transaminease, glutamic-pyruvic transaminase, urea, inosine, uric acid, urine ketoboidies are all in normal range (NR), criterion in " function of health food is learned assessment process and the method for inspection " of promulgating according to the Ministry of Public Health, think that having the weight reducing capsules A that strengthens immunity function concurrently has weight losing function.
Replace having the weight reducing capsules A that strengthens immunity function concurrently with having the weight reducing capsule B that strengthens immunity function, the weight reducing capsule C that has the enhancing immunity function concurrently concurrently, repeat above-mentioned experiment, result is without significant change.
Above-mentioned experiment demonstration, the present invention has the weight reducing capsule that strengthens immunity function concurrently and has obvious weight losing function, and long-term taking, without digestive discomfort.
The present invention includes but be not limited to above-mentioned embodiment, any product that meets the description of these claims, within all falling into protection scope of the present invention.
Claims (2)
1. one kind has the weight reducing capsule that strengthens immunity function concurrently, it is characterized in that: the fleece-flower root of the grape seed extract of the propolis of the konjaku that its capsule 's content comprises the 144-176 weight portion, 27-33 weight portion, the pearl powder of 27-33 weight portion, 22.5-27.5 weight portion, the American Ginseng of 27-33 weight portion, 54-66 weight portion, the lotus leaf of 36-44 weight portion, the rhizoma alismatis of 22.5-27.5 weight portion.
2. the weight reducing capsule that strengthens immunity function that has concurrently according to claim 1, it is characterized in that: every has the weight reducing capsule that strengthens immunity function concurrently and contains:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310055848XA CN103141836A (en) | 2013-02-21 | 2013-02-21 | Weight reducing capsule capable of enhancing immunity functions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310055848XA CN103141836A (en) | 2013-02-21 | 2013-02-21 | Weight reducing capsule capable of enhancing immunity functions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103141836A true CN103141836A (en) | 2013-06-12 |
Family
ID=48540395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310055848XA Pending CN103141836A (en) | 2013-02-21 | 2013-02-21 | Weight reducing capsule capable of enhancing immunity functions |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103141836A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107224499A (en) * | 2017-06-01 | 2017-10-03 | 广东省阳春市信德生物科技发展有限公司 | A kind of slimming capsule |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01224320A (en) * | 1988-03-01 | 1989-09-07 | Shimizu Kagaku Kk | Reduction of food ingestion amount using glucomannan without accompanying decrease of body weight |
| CN1380068A (en) * | 2002-04-29 | 2002-11-20 | 池寒峰 | Medicine for curing enterogastric diseases and its preparation method |
| CN1389265A (en) * | 2001-06-05 | 2003-01-08 | 北京西开国泰医药科技有限责任公司 | Composite Chinese medicine with health care function |
| CN1544039A (en) * | 2003-11-14 | 2004-11-10 | 深圳市仁德堂实业有限公司 | Fat-reducing speckle-removing cosmetic mixture and its capsule |
| CN1824086A (en) * | 2005-12-30 | 2006-08-30 | 武汉代代木生物科技有限公司 | Health protection capsule |
| CN101756187A (en) * | 2008-10-22 | 2010-06-30 | 于树丽 | American ginseng multiflower knotweed root buccal tablet |
| CN102772596A (en) * | 2012-08-05 | 2012-11-14 | 韩树叶 | Weight-losing and vein-dredging capsules and preparation technology thereof |
-
2013
- 2013-02-21 CN CN201310055848XA patent/CN103141836A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01224320A (en) * | 1988-03-01 | 1989-09-07 | Shimizu Kagaku Kk | Reduction of food ingestion amount using glucomannan without accompanying decrease of body weight |
| CN1389265A (en) * | 2001-06-05 | 2003-01-08 | 北京西开国泰医药科技有限责任公司 | Composite Chinese medicine with health care function |
| CN1380068A (en) * | 2002-04-29 | 2002-11-20 | 池寒峰 | Medicine for curing enterogastric diseases and its preparation method |
| CN1544039A (en) * | 2003-11-14 | 2004-11-10 | 深圳市仁德堂实业有限公司 | Fat-reducing speckle-removing cosmetic mixture and its capsule |
| CN1824086A (en) * | 2005-12-30 | 2006-08-30 | 武汉代代木生物科技有限公司 | Health protection capsule |
| CN101756187A (en) * | 2008-10-22 | 2010-06-30 | 于树丽 | American ginseng multiflower knotweed root buccal tablet |
| CN102772596A (en) * | 2012-08-05 | 2012-11-14 | 韩树叶 | Weight-losing and vein-dredging capsules and preparation technology thereof |
Non-Patent Citations (1)
| Title |
|---|
| 京东网上商城: "汤臣倍健纤巧纤纤胶囊", 《HTTP:ITEM.JD.COM/1002549120.HTML-汤臣倍健纤巧纤纤胶囊》, 25 December 2011 (2011-12-25), pages 3 - 4 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107224499A (en) * | 2017-06-01 | 2017-10-03 | 广东省阳春市信德生物科技发展有限公司 | A kind of slimming capsule |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101015603A (en) | Medicine composition with fat-reducing and bowel relaxing functions, preparing process and quality controlling means thereof | |
| CN107772433A (en) | One kind, which has, alleviates physical fatigue, strengthen immunity composition and preparation method thereof | |
| CN102526477A (en) | Medicine composition for enhancing immunities as well as preparation method and application thereof | |
| CN103829234A (en) | Health food capable of improving immunity and reducing blood fat and preparation method thereof | |
| CN101461918B (en) | Medicament composition for treating male climacteric syndrome and delaying age | |
| CN104127577A (en) | Chinese medicine capsule for relieving physical fatigue and preparation method of Chinese medicine capsule | |
| CN105055855B (en) | With Chinese medicine composition for improving sleep, strengthen immunity effect and its preparation method and application | |
| CN104012982A (en) | Health care product composition with immunity increasing function, soft capsule and preparation method thereof | |
| CN103141836A (en) | Weight reducing capsule capable of enhancing immunity functions | |
| CN107802695A (en) | A kind of health composition of the strengthen immunity containing saline cistanche and preparation method thereof | |
| CN102475201A (en) | Protein powder composition with health care function | |
| CN103330898B (en) | Traditional Chinese medicine composition for curing impotence and prospermia, as well as preparation method and application of traditional Chinese medicine composition | |
| CN103550409B (en) | Pharmaceutical composition of a kind of fat-reducing and preparation method thereof | |
| CN102670953A (en) | Heath-care slimming liquid | |
| CN101229220B (en) | Compound for preventing and curing pseudomyopia and preparing method thereof | |
| CN101322739B (en) | Prescription of Chinese medicine health care capsules mixed with nucleotide and aminoacid and preparing technique | |
| CN104489692A (en) | Health food with natural source resveratrol and making method thereof | |
| CN103976216A (en) | Health-protection product with functions of supplementing calcium and enhancing immunity and preparation method for health-protection product | |
| CN101803732B (en) | Health-care food with blood-fat reduction assistance function and preparation method thereof | |
| CN104189038A (en) | Traditional Chinese medicine preparation for regulating female physical health and immunity | |
| CN101015659A (en) | Health-care food for reducing blood sugar on the assistant role and its preparing process | |
| CN109394713A (en) | Compound Fenbendazole Pyrantel and preparation method thereof | |
| CN104042790B (en) | A kind of pharmaceutical composition and its application for health care for the middle and old aged | |
| CN107126484A (en) | It is a kind of to treat callicarpa nudiflora gel of gynaecological imflammation and preparation method thereof | |
| CN116077604B (en) | Traditional Chinese medicine composition for assisting in reducing blood sugar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130612 |